NO20054006D0 - Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer - Google Patents

Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer

Info

Publication number: NO20054006D0
Authority: NO; Norway
Prior art keywords: same; preparation process; kinase inhibitors; pharmaceutical use; urea derivatives
Prior art date: 2003-01-31

Application number

NO20054006A

Other languages

English (en)

Other versions

NO20054006L (no

Inventor

Jean-Luc Malleron

Augustin Hittinger

Jacques Mauger

Herve Bouchard

Hartmut Strobel

Youssef El-Ahmad

Fahad A D Al-Obeidi

Conception Nemecek

Thomas H Faitg

Marcel Patek

Anil Nair

Daniel Bond

Greg Harlow

Mark Palermo

Sven Ruf

Kurt Ritter

Dominique Lesuisse

Didier Benard

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-31

Filing date

2005-08-29

Publication date

2005-08-29

2005-08-29 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2005-08-29 Publication of NO20054006D0 publication Critical patent/NO20054006D0/no

2005-10-13 Publication of NO20054006L publication Critical patent/NO20054006L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

NO20054006A 2003-01-31 2005-08-29 Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer NO20054006L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0301098A FR2850652B1 (fr)	2003-01-31	2003-01-31	Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
PCT/FR2004/000188 WO2004070050A2 (fr)	2003-01-31	2004-01-28	Derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Publications (2)

Publication Number	Publication Date
NO20054006D0 true NO20054006D0 (no)	2005-08-29
NO20054006L NO20054006L (no)	2005-10-13

Family

ID=32696243

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054006A NO20054006L (no)	2003-01-31	2005-08-29	Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer

Country Status (24)

Country	Link
EP (1)	EP1599464B1 (no)
JP (1)	JP4604020B2 (no)
KR (1)	KR20050098286A (no)
CN (1)	CN1768054A (no)
AR (1)	AR042936A1 (no)
AT (1)	ATE482207T1 (no)
AU (1)	AU2004209319A1 (no)
BR (1)	BRPI0407091A (no)
CA (1)	CA2513631A1 (no)
DE (1)	DE602004029236D1 (no)
FR (1)	FR2850652B1 (no)
HR (1)	HRP20050679A2 (no)
MA (1)	MA27651A1 (no)
ME (1)	MEP22608A (no)
MX (1)	MXPA05007407A (no)
NO (1)	NO20054006L (no)
NZ (1)	NZ541270A (no)
PE (1)	PE20040808A1 (no)
PL (1)	PL377811A1 (no)
RS (1)	RS20050657A (no)
RU (1)	RU2341523C2 (no)
TW (1)	TW200505898A (no)
WO (1)	WO2004070050A2 (no)
ZA (1)	ZA200505934B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE027546T2 (en) *	2003-08-29	2016-10-28	Brigham & Womens Hospital Inc	Hydantoin derivatives as cell necrosis inhibitors
US7700603B2 (en)	2003-12-15	2010-04-20	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US7763609B2 (en)	2003-12-15	2010-07-27	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US7592348B2 (en)	2003-12-15	2009-09-22	Schering Corporation	Heterocyclic aspartyl protease inhibitors
AU2004305075A1 (en)	2003-12-19	2005-07-07	The Regents Of The University Of California	Methods and materials for assessing prostate cancer therapies
NZ550102A (en)	2004-02-24	2010-10-29	Univ California	Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
EP1621536A1 (en) *	2004-07-27	2006-02-01	Aventis Pharma S.A.	Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621535A1 (en) *	2004-07-27	2006-02-01	Aventis Pharma S.A.	Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7709517B2 (en)	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
AU2007245022A1 (en)	2006-03-29	2007-11-08	The Regents Of The University Of California	Diarylthiohydantoin compounds
AU2006248109B2 (en)	2005-05-13	2012-11-15	The Regents Of The University Of California	Diarylhydantoin compounds
US7709516B2 (en) *	2005-06-17	2010-05-04	Endorecherche, Inc.	Helix 12 directed non-steroidal antiandrogens
FR2896503B1 (fr) *	2006-01-23	2012-07-13	Aventis Pharma Sa	Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896504B1 (fr)	2006-01-23	2012-07-13	Aventis Pharma Sa	Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
DK3100727T3 (en)	2006-03-27	2018-11-12	Univ California	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
JP2010500300A (ja)	2006-08-08	2010-01-07	サノフィ−アベンティス	アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
JP2010512389A (ja)	2006-12-12	2010-04-22	シェーリングコーポレイション	アスパルチルプロテアーゼ阻害剤
WO2009055053A2 (en)	2007-10-26	2009-04-30	The Regents Of The University Of California	Diarylhydantoin compounds as androgen receptor modulators
US20120122889A1 (en)	2008-12-23	2012-05-17	President And Fellows Of Harvard College	Small molecule inhibitors of necroptosis
EP3124481B1 (en)	2010-02-16	2018-03-28	Aragon Pharmaceuticals, Inc.	Androgen receptor modulators and uses thereof
US8685256B2 (en) *	2010-12-21	2014-04-01	Cytec Technology Corp.	Microdispersions of hydroxamated polymers and methods of making and using them
US8492556B2 (en) *	2011-11-10	2013-07-23	Allergan, Inc.	2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
SG10201912719TA (en)	2012-09-26	2020-02-27	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar)	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
EP2968276A4 (en)	2013-03-15	2017-02-15	President and Fellows of Harvard College	Hybrid necroptosis inhibitors
GB201312492D0 (en) *	2013-07-12	2013-08-28	Syngenta Ltd	Herbicidal compounds
US10202373B2 (en)	2014-01-14	2019-02-12	Millennium Pharmaceuticals, Inc.	Heteroaryls and uses thereof
KR20160122736A (ko)	2014-01-14	2016-10-24	밀레니엄 파머슈티컬스 인코퍼레이티드	헤테로아릴 및 이의 용도
CN107530350A (zh)	2014-12-11	2018-01-02	哈佛理事会	细胞坏死抑制剂及相关方法
TWI726969B (zh)	2016-01-11	2021-05-11	比利時商健生藥品公司	用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107619388A (zh) *	2016-07-13	2018-01-23	南京天印健华医药科技有限公司	作为fgfr抑制剂的杂环化合物
HRP20241015T1 (hr) *	2016-07-20	2024-11-08	Novartis Ag	Derivati aminopiridina i njihova uporaba kao selektivnih alk-2 inhibitora
JP7201694B2 (ja)	2017-10-16	2023-01-10	アラゴンファーマシューティカルズ，インコーポレイテッド	非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤
WO2019088677A1 (ko) *	2017-10-31	2019-05-09	광주과학기술원	급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
TW202517640A (zh) *	2023-07-18	2025-05-01	愛爾蘭商赫瑞森治療學愛爾蘭指定活動公司	用於治療疾病之ｉｇｆ－１ｒ的雜環抑制劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2329276A1 (fr) *	1975-10-29	1977-05-27	Roussel Uclaf	Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE4228717A1 (de) *	1992-08-28	1994-03-03	Cassella Ag	Imidazolidin-Derivate
DE19540027A1 (de) *	1995-10-27	1997-04-30	Gruenenthal Gmbh	Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
TR199902124T2 (xx) *	1997-03-03	2000-06-21	Boehringer Ingelheim Pharmaceuticals, Inc.	�ltihapl� hastal�klar�n tedavisinde yararl� k��k molek�ller.
DE19732928C2 (de) *	1997-07-31	2000-05-18	Gruenenthal Gmbh	Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
FR2796945B1 (fr) *	1999-07-30	2002-06-28	Sod Conseils Rech Applic	Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
JP3924531B2 (ja) *	2000-05-31	2007-06-06	田辺製薬株式会社	αＬβ２介在細胞接着阻害剤
AU2003242249A1 (en) *	2002-05-16	2003-12-02	Bayer Cropscience Gmbh	Pyridine carboxamide derivatives and their use as pesticides

2003
- 2003-01-31 FR FR0301098A patent/FR2850652B1/fr not_active Expired - Fee Related
2004
- 2004-01-22 PE PE2004000090A patent/PE20040808A1/es not_active Application Discontinuation
- 2004-01-27 AR ARP040100233A patent/AR042936A1/es unknown
- 2004-01-28 BR BR0407091-7A patent/BRPI0407091A/pt not_active IP Right Cessation
- 2004-01-28 CN CNA2004800088356A patent/CN1768054A/zh active Pending
- 2004-01-28 PL PL377811A patent/PL377811A1/pl not_active Application Discontinuation
- 2004-01-28 RS YUP-2005/0657A patent/RS20050657A/sr unknown
- 2004-01-28 ME MEP-226/08A patent/MEP22608A/xx unknown
- 2004-01-28 KR KR1020057014096A patent/KR20050098286A/ko not_active Ceased
- 2004-01-28 JP JP2006502123A patent/JP4604020B2/ja not_active Expired - Fee Related
- 2004-01-28 NZ NZ541270A patent/NZ541270A/en unknown
- 2004-01-28 WO PCT/FR2004/000188 patent/WO2004070050A2/fr not_active Ceased
- 2004-01-28 HR HR20050679A patent/HRP20050679A2/xx not_active Application Discontinuation
- 2004-01-28 EP EP04705838A patent/EP1599464B1/fr not_active Expired - Lifetime
- 2004-01-28 CA CA002513631A patent/CA2513631A1/fr not_active Abandoned
- 2004-01-28 DE DE602004029236T patent/DE602004029236D1/de not_active Expired - Lifetime
- 2004-01-28 AU AU2004209319A patent/AU2004209319A1/en not_active Abandoned
- 2004-01-28 AT AT04705838T patent/ATE482207T1/de not_active IP Right Cessation
- 2004-01-28 MX MXPA05007407A patent/MXPA05007407A/es active IP Right Grant
- 2004-01-28 RU RU2005127335/04A patent/RU2341523C2/ru not_active IP Right Cessation
- 2004-01-30 TW TW093102064A patent/TW200505898A/zh unknown
2005
- 2005-07-22 ZA ZA200505934A patent/ZA200505934B/en unknown
- 2005-07-29 MA MA28417A patent/MA27651A1/fr unknown
- 2005-08-29 NO NO20054006A patent/NO20054006L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
RU2005127335A (ru)	2006-09-10
TW200505898A (en)	2005-02-16
BRPI0407091A (pt)	2006-01-24
JP2006517569A (ja)	2006-07-27
ZA200505934B (en)	2007-06-27
RS20050657A (sr)	2007-06-04
MEP22608A (en)	2010-06-10
EP1599464A2 (fr)	2005-11-30
MA27651A1 (fr)	2005-12-01
MXPA05007407A (es)	2005-09-12
RU2341523C2 (ru)	2008-12-20
NO20054006L (no)	2005-10-13
CA2513631A1 (fr)	2004-08-19
HRP20050679A2 (en)	2006-12-31
CN1768054A (zh)	2006-05-03
PL377811A1 (pl)	2006-02-20
ATE482207T1 (de)	2010-10-15
PE20040808A1 (es)	2004-12-31
DE602004029236D1 (de)	2010-11-04
WO2004070050A2 (fr)	2004-08-19
KR20050098286A (ko)	2005-10-11
FR2850652A1 (fr)	2004-08-06
NZ541270A (en)	2008-11-28
AR042936A1 (es)	2005-07-06
JP4604020B2 (ja)	2010-12-22
FR2850652B1 (fr)	2008-05-30
AU2004209319A1 (en)	2004-08-19
EP1599464B1 (fr)	2010-09-22
WO2004070050A3 (fr)	2005-02-17

Publication	Publication Date	Title
NO20054006D0 (no)	2005-08-29	Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer
IL180488A0 (en)	2007-06-03	Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof of kinase inhibitors
IL180286A0 (en)	2007-07-04	Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
IL180257A0 (en)	2007-07-04	Heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
NO20054905D0 (no)	2005-10-24	2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20034187D0 (no)	2003-09-19	Nye spirotricykliske derivater og anvendelse derav som fosfodiesterase-7 inhibitorer
IS7543A (is)	2004-11-22	Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær
NO20053356D0 (no)	2005-07-11	Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
DK1523488T3 (da)	2009-03-16	Nye thiophenglycosidderivater, fremgangsmåder til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
AP2064A (en)	2009-10-30	Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
DK1368349T3 (da)	2007-05-21	Xanthinderivater, deres fremstilling og deres anvendelse som lægemidler
NO20054244D0 (no)	2005-09-13	Nitrogeninneholdende heterocykliske derivater og legemidler inneholdende de samme som den aktive bestanddel
EE200300327A (et)	2003-10-15	Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
EE200300581A (et)	2004-02-16	Karboksamiid-asendatud fenüüluurea derivaadid ja nende kasutamine, ravim ja selle valmistamismeetod
IL192440A0 (en)	2009-02-11	Sulphur-containing cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
NO20055204D0 (no)	2005-11-04	Derivater av piperidinyl- og pipemzinylalkylkarbamater, fremgangsmater for fremstilling derav og anvendelse av de samme i terapi
CY2017048I2 (el)	2018-09-05	Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
DK1670458T3 (da)	2007-04-23	1-Amino-2-oxy-substituerede tetrahydronaphthalenderivater, fremgangsmåder til fremstilling deraf og deres anvendelse som antiphlogistika
IL192442A0 (en)	2008-12-29	Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
IL182054A0 (en)	2007-07-24	Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
NO20054876D0 (no)	2005-10-21	Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
DK1494650T3 (da)	2011-08-08	Farmaceutisk formulering, der indeholder melatonin
NO20053809D0 (no)	2005-08-12	Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
NO20055835L (no)	2006-02-07	Cykliske aminderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20053588L (no)	2005-09-22	Acylaminotiazol-derivater, fremstilling og anvendelse derav som beta-amyloidpeptid-produksjonsinhibitorer.

Legal Events

Date	Code	Title	Description
2010-08-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application